Roškar Samo, Antolič Vane, Mavčič Blaž
Faculty of Medicine, University of Ljubljana, Zaloška 9, SI-1000 Ljubljana, Slovenia.
Department of Orthopaedic Surgery, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Zaloška 9, SI-1000 Ljubljana, Slovenia.
Indian J Orthop. 2022 Sep 5;56(11):1969-1977. doi: 10.1007/s43465-022-00733-1. eCollection 2022 Nov.
The EcoFit total hip endoprosthesis has recently been approved for clinical use in the USA as a substantially equivalent implant to the Taperloc Hip System, but no report has directly compared their long-term results so far. The primary aim of the presented single-hospital EcoFit cohort analysis was to determine femoral stem survival rates at 5/10 years of follow-up in comparison to eight Taperloc studies published within the last decade (2011-2021). The secondary aim was to find out whether femoral stem survival depended on the patients' age, gender and the operating surgeon.
The retrospective surgeon-stratified observational cohort study included 680 consecutive patients with primary EcoFit femoral stem implanted at the same operating theatre block of a single tertiary hospital between April 2009 and December 2015. Survival analyses after 6-12 years of follow-up were performed with the Kaplan-Meier method and the Cox regression.
The cumulative proportion of revision-free surviving EcoFit femoral stems 5/10 years after the primary implantation was 96/94%, respectively, and the cumulative proportion of unremoved stems was 99/98%, respectively. The EcoFit stem revision rate of 0.46 per 100 components-years was not significantly different from most Taperloc cohorts. Higher age increased the risk of subsequent EcoFit femoral stem revision (hazard ratio 1.039, = 0.048) while the impact of gender and the operating surgeon was not statistically significant.
The study presents the first surgeon-stratified cohort analysis of the EcoFit-Implantcast femoral stem from a single hospital with 5851 component years of observation. Long-term EcoFit survival rates are comparable to the Taperloc hip system. Caution is warranted when using such flat cementless single-wedge stems in the elderly population.
EcoFit全髋关节假体最近在美国被批准用于临床,被视为与Taperloc髋关节系统基本等效的植入物,但目前尚无报告直接比较它们的长期效果。本单中心EcoFit队列分析的主要目的是确定在5/10年随访时股骨柄的生存率,并与过去十年(2011 - 2021年)发表的八项Taperloc研究进行比较。次要目的是了解股骨柄生存率是否取决于患者的年龄、性别和手术医生。
这项回顾性的、按手术医生分层的观察性队列研究纳入了2009年4月至2015年12月期间在一家三级医院的同一手术室区域连续植入原发性EcoFit股骨柄的680例患者。采用Kaplan-Meier法和Cox回归进行6 - 12年随访后的生存分析。
初次植入后5/10年,EcoFit股骨柄无翻修存活的累积比例分别为96%/94%,未取出柄的累积比例分别为99%/98%。EcoFit柄的翻修率为每100个部件年0.46,与大多数Taperloc队列相比无显著差异。年龄较大增加了后续EcoFit股骨柄翻修的风险(风险比1.039,P = 0.048),而性别和手术医生的影响无统计学意义。
本研究呈现了来自一家单中心、对EcoFit-Implantcast股骨柄进行的首次按手术医生分层的队列分析,观察了5851个部件年。EcoFit的长期生存率与Taperloc髋关节系统相当。在老年人群中使用这种扁平无骨水泥单楔柄时需谨慎。